ArticleJournal of diabetes research2026
Depression and Its Association With Microvascular and Macrovascular Complications in Type 2 Diabetes.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) and depression frequently co-occur, but the specific clinical factors driving this association remain incompletely understood, particularly in Middle Eastern populations.
objectiveThis study is aimed at investigating the association between T2DM and depression and identifying which clinical factors (complications, glycemic control, and treatment modality) are most strongly associated with depression risk in a Syrian patient cohort.
methodsA case-control study enrolled 225 patients with T2DM and 226 nondiabetic controls. Depression was assessed using the Hamilton Depression Rating Scale (HDRS) and the Depression, Anxiety, and Stress Scales (DASS-21). Associations were analyzed using chi-square tests and binary logistic regression, with adjustment for age and sex in subgroup analyses.
resultsDepression prevalence was significantly higher in the T2DM group (68.4% by HDRS and 68.9% by DASS-21) than in controls (40.3% and 41.6%, respectively). A T2DM diagnosis was associated with approximately threefold increased odds of depression (OR = 3.22, 95% CI [2.19-4.74] for HDRS; OR = 3.12, 95% CI [2.11-4.58] for DASS-21). Microvascular complications were associated with a marked increase in depression odds (OR = 17.05 - 17.89). Achieving glycemic control was strongly protective (OR = 0.116 - 0.125). Complex insulin-based regimens were associated with greater depression severity, even when the binary presence of depression did not differ significantly by treatment type.
conclusionIn this Syrian cohort, T2DM was associated with a threefold higher odds of depression, but this risk was not uniform. The presence of microvascular complications was the strongest associated factor. These findings support the implementation of routine depression screening in diabetes care, particularly for patients with complications or complex treatment regimens, and highlight that intensive diabetes management may also contribute to depression prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.